Original Article
Subject Category: Melanocytes/Melanoma
Journal of Investigative Dermatology (2008) 128, 2013–2023; doi:10.1038/jid.2008.44; published online 6 March 2008
Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells
Konstantinos G Lasithiotakis1,4, Tobias W Sinnberg1,4, Birgit Schittek1, Keith T Flaherty2, Dagmar Kulms3, Evelyn Maczey1, Claus Garbe1 and Friedegund E Meier1
- 1Division of Dermatologic Oncology, Department of Dermatology, University of Tuebingen, Tuebingen, Germany
- 2Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA
- 3Institute of Cell Biology and Immunology, University of Stuttgart, Germany
Correspondence: Dr Friedegund E. Meier, Division of Dermatologic Oncology, Department of Dermatology, University of Tuebingen, Liebermeisterstr. 25, Tuebingen D-72076, Germany. E-mail: friedegund.meier@med.uni-tuebingen.de
4These authors contributed equally to this work
Received 30 July 2007; Accepted 8 January 2008; Published online 6 March 2008.
Abstract
The RAS–RAF–MEK–ERK and PI3K–AKT–mTOR signaling pathways are activated through multiple mechanisms and appear to play a major role in melanoma progression. Herein, we examined whether targeting the RAS–RAF–MEK–ERK pathway with the RAF inhibitor sorafenib and/or the PI3K–AKT–mTOR pathway with the mTOR inhibitor rapamycin has therapeutic effects against melanoma. A combination of sorafenib (4
M) with rapamycin (10 nM) potentiated growth inhibition in all six metastatic melanoma cell lines tested. The absolute enhancement of growth inhibition rates ranged from 13.0–27.8% in different cell lines (P<0.05, combination treatment vs monotreatment). Similar results were obtained with combinations of the MEK inhibitors U0126 (30
M) or PD98059 (50
M) with rapamycin (10 nM). The combined treatment of melanoma cells with sorafenib and rapamycin led to an approximately twofold increase of cell death compared with sorafenib monotreatment (P<0.05) as assessed by propidium iodide staining and cell death detection ELISA. Moreover, sorafenib in combination with rapamycin completely suppressed invasive melanoma growth in organotypic culture mimicking the physiological context. These effects were associated with complete downregulation of the antiapoptotic proteins Bcl-2 and Mcl-1. Sorafenib combined with rapamycin appears to be a promising strategy for the effective treatment of melanoma and merits clinical investigation.
Abbreviations:
Bcl-1, B-cell lymphoma-2; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; Mcl-1, myeloid cell leukemia-1; MEK, MAPK/ERK kinase; PBS, phosphate-buffered saline; RAF, recombinant activated factor
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Oxygen deprivation provokes melanomaNature Medicine News and Views (01 Feb 2006)
Embryogenesis meets tumorigenesisNature Medicine News and Views (01 Aug 2006)
RESEARCH
Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and TemozolomideJournal of Investigative Dermatology Original Article
See all 24 matches for Research


